Peer Review Journals
Conference Abstracts
Oral / Platform Presentations
Poster Presentations
Peer Review Journal
Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
J Brettschneider, TD Jaskowski, H Tumani, S Abdul, D Husebye, H Seraj, HR Hill, E Fire, L Spector, J Yarden , N Dotan and JW Rose
J Neuroimmunol 2009; 217;95-101
Anti-alpha-glucose based glycan IgM antibodies predict relapse Activity in Multiple Sclerosis after the first neurological event.
MS Freedman, J Laks, N Dotan, RT Altstock, A Dukler, and CJM Sindic
Mult Scler 2009; 15: 422-430.
Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
M Schwarz , L Spector , M Gortler , O Weishaus , L Glass-Marmor , A Karni , N Dotan , A Miller
J Neurol Sci 2006;244:59-68.
Conference Abstracts
Oral / Platform Presentations
2006 AUTOIMMUNITY 5th International Congress:
Prognosis in Multiple Sclerosis.
C Sindic. Abstracts of 5th international Congress on Autoimmunity , Autoimmunity Reviews.
2006; ISSN 1568-9972:p 203.
2009 ACTRIMS
H Tumani, J Brettschneider, TD Jaskowski, S Abdul, D Husebye, H Seraj, HR Hill, E Fire, J Yarden, L Spector, N Dotan, JW Rose
2009 ECTRIMS:
Anti-alpha-glucose based glycan IgM antibodies in patients with a clinically isolated syndrome:
analyses from the BEtageron® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study
M Freedman, G Edan, HP Hartung, L Kappos, D Miller, X Montalban, CH Polman, N Dotan, V Lanius,
C Metzig, S Schwenke, C Pohl, R Sandbrink for the BENEFIT Study Group
Mult Scler 2009; 15: S71.
2008 ACTRIMS/ECTRIMS/LACTRIMS Joint Meeting:
Performance of an anti-GAGA4 IgM assay in distinguishing multiple sclerosis patients from control groups in a US cohort: a cross sectional retrospective study
TD Jaskowski, D Husebye, HS Seraj, J Yarden, L Spector, E Fire, N Dotan, HR Hill, JW Rose
Mult Scler 2008; 14: S282.
|
